GSK’s (GSK) “Hold” Rating Reiterated at Deutsche Bank Aktiengesellschaft

GSK (LON:GSK)‘s stock had its “hold” rating restated by research analysts at Deutsche Bank Aktiengesellschaft in a research note issued on Tuesday, Digital Look reports. They currently have a GBX 2,000 price objective on the stock. Deutsche Bank Aktiengesellschaft’s price objective indicates a potential upside of 7.76% from the stock’s current price.

GSK has been the subject of a number of other reports. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,500 price target on shares of GSK in a research report on Wednesday, July 29th. Berenberg Bank boosted their price objective on GSK from GBX 2,000 to GBX 2,200 and gave the stock a “hold” rating in a research report on Tuesday, September 15th. Finally, Royal Bank Of Canada restated a “sector perform” rating and issued a GBX 1,975 price objective on shares of GSK in a research note on Tuesday, September 8th. Two investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, GSK has an average rating of “Hold” and an average price target of GBX 2,064.38.

GSK Stock Down 0.2%

LON:GSK traded down GBX 4 on Tuesday, hitting GBX 1,856. The stock had a trading volume of 8,473,180 shares, compared to its average volume of 12,879,812. The company has a debt-to-equity ratio of 103.36, a quick ratio of 0.73 and a current ratio of 0.82. The stock has a market cap of £74.37 billion, a P/E ratio of 15.76, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29. GSK has a 1 year low of GBX 1,520.50 and a 1 year high of GBX 2,282. The firm’s fifty day simple moving average is GBX 1,886.30 and its two-hundred day simple moving average is GBX 1,945.14.

GSK (LON:GSK) last posted its earnings results on Tuesday, July 28th. The company reported GBX 10.80 EPS for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. Analysts predict that GSK will post 175.980975 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Anne Beal purchased 637 shares of the business’s stock in a transaction dated Friday, September 18th. The stock was purchased at an average cost of GBX 4,985 per share, with a total value of £31,754.45. Also, insider Jonathan Symonds purchased 1,500 shares of the business’s stock in a transaction dated Friday, September 18th. The stock was bought at an average cost of GBX 1,881 per share, with a total value of £28,215. Insiders have acquired a total of 2,144 shares of company stock worth $6,009,566 in the last three months. Insiders own 0.20% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.